Catalyst
Slingshot members are tracking this event:
Pfizer's (PFE) Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented as Late-Breaking Data at the ESC Congress 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PFE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 27, 2018
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Tafamidis, Phase 3b, Transthyretin Amyloid Cardiomyopathy
